Table 2.
Selected therapy characteristics of the total study cohort with univariable analyses of BB-CAM use
| CHARACTERISTICS | ALL PATIENTS | BB-CAM | p 1 | |||||
|---|---|---|---|---|---|---|---|---|
| User | Non-user | |||||||
| Total Count | % of all patients | Count | % of Total | Count | % of Total | |||
| 448 | 100% | 332 | 74.1% | 116 | 25.9% | |||
| Therapy line | 0.053 | |||||||
| Breast-Ca | Neoadjuvant | 70 | 15.6% | 58 | 82.9% | 12 | 17.1% | |
| Adjuvant | 89 | 19.9% | 64 | 71.9% | 25 | 28.1% | ||
| Metastasis 1st -line | 78 | 17.4% | 45 | 57.7% | 33 | 42.3% | ||
| Metastasis 2nd -line | 50 | 11.2% | 37 | 74.0% | 13 | 26.0% | ||
| Metastasis 3rd -line | 20 | 4.5% | 17 | 85.0% | 3 | 15.0% | ||
| Metastasis ≥4th -line | 53 | 11.8% | 42 | 79.2% | 11 | 20.8% | ||
| Recurrence 1st -line | 8 | 1.8% | 6 | 75.0% | 2 | 25.0% | ||
| Recurrence ≥ 2nd -line | 5 | 1.1% | 3 | 60.0% | 2 | 40.0% | ||
| Ovarian-Ca | Neoadjuvant | 1 | 0.2% | 1 | 100.0% | 0 | 0.0% | |
| Adjuvant | 37 | 8.3% | 29 | 78.4% | 8 | 21.6% | ||
| Recurrent | 37 | 8.3% | 30 | 81.1% | 7 | 18.9% | ||
| Therapy | ||||||||
| Immune modulation | 2 | 0.4% | 2 | 100.0% | 0 | 0.0% | 0.402 | |
| Chemotherapy | 278 | 62.1% | 220 | 79.1% | 58 | 20.9% | 0.002 | |
| Antibodies | 196 | 43.8% | 143 | 73.0% | 53 | 27.0% | 0.625 | |
| Endocrine | 150 | 33.5% | 100 | 66.7% | 50 | 33.3% | 0.011 | |
| Bisphosphonates | 129 | 28.8% | 87 | 67.4% | 42 | 32.6% | 0.041 | |
1p values are not adjusted for multiplicity and have to be interpreted to be exploratory